Prestige Consumer Healthcare (PBH)
NYSEHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$52.26-0.57%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · PBH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.0% |
| Our one-year growth estimate | diamond | 15.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 44.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 3 industry peers · Company calendar date is not available
PBH — President transition
Dated 2026-08-14
Senior Vice President, Operations — Jeffrey Zerillo: The executive is retiring from a senior operational role, which constitutes an orderly succession rather than a sudden loss or shock departure.
Why it matters: This offering will refinance debt. It may change cash flow and capital use.
Watch forThe offering was completed. It helps the company's debt.
Also watch forThe offering fails or leads to higher-than-expected debt costs.
Why it matters: Less debt means better financial health. It shows good management of money.
Supportive ifManagement says net debt decreased after merging the companies. Cash flow also improved.
Worry ifNet debt goes up or stays the same, even with better cash flow.
Why it matters: Management wants to boost operating income. This is key for making money.
Supportive ifOperating income for fiscal 2027 is higher than $309.4 million in fiscal 2026.
Worry ifOperating income for fiscal 2027 drops or stays below $309.4 million.
Why it matters: This acquisition could boost growth and show management's commitment to expansion. Investors will look for signs of how this affects revenue.
Supportive ifLook for positive revenue growth in the next quarter after the acquisition.
Worry ifRevenue growth fails to improve or declines in the next quarter after the acquisition.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$160 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $325 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,528 loss on $10,000 · 35.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: EPS growth shows the company can manage costs and use acquisitions well.
Supportive ifAdjusted diluted EPS exceeds $1.10 in Q2 fiscal 2027.
Worry ifAdjusted diluted EPS falls below $1.00 in Q2 fiscal 2027.
Why it matters: A rise in operating income shows good cost control and focus on profit.
Supportive ifOperating income in Q2 goes up to $52.5 million.
Worry ifOperating income in Q2 goes down to $52.5 million.
Why it matters: Strong free cash flow helps reduce debt and plan capital use.
Supportive ifFree cash flow exceeds $270 million in fiscal 2027.
Worry ifFree cash flow falls below $250 million in fiscal 2027.
Why it matters: Strong free cash flow helps with spending and managing debt.
Supportive ifFree cash flow in Q2 exceeds $83 million.
Worry ifFree cash flow in Q2 falls below $83 million.
Why it matters: Closing the LaCorium deal will expand Prestige's product offerings in skin care. This could boost revenue and market position.
Supportive ifThe acquisition will close as planned in Q2 fiscal 2027. It is expected to bring in $40 million.
Worry ifThe acquisition may be delayed or not close. This could hurt growth expectations.
Why it matters: This acquisition is likely to bring in more money. It tests how well management grows.
Supportive ifQ2 revenue increases by at least $6 million due to the Breathe Right acquisition.
Worry ifQ2 revenue does not show any increase from the Breathe Right acquisition.
Why it matters: Fixing the last earnings miss is important for gaining back investor trust.
Worry ifQ1 earnings show a big improvement from the last quarter.
Less concerning ifEarnings miss expectations again or show no improvement from the last quarter.
Why it matters: This will show if the company can address the recent earnings miss. Investors will focus on any recovery in operating income.
Watch forEarnings per share are better than expected. This shows signs of recovery.
Also watch forEarnings per share falls short of expectations, confirming ongoing issues.
Why it matters: If operating income keeps falling, it may show bigger profit problems. This can hurt investor trust.
Worry ifOperating income is below $75.5M in the next quarter.
Less concerning ifOperating income is above $75.5M in the next quarter.
Why it matters: Earnings results will show how well Prestige is handling its new acquisitions and supply issues.
Watch forReported earnings per share exceeds the guidance range of $4.42 to $4.51.
Also watch forEarnings per share drops below the guidance range. This shows ongoing challenges.
Why it matters: This growth shows how well the company is managing its new acquisitions and existing brands.
Supportive ifOrganic revenue growth exceeds 3% in Q2 fiscal 2027.
Worry ifOrganic revenue growth falls below 1% in Q2 fiscal 2027.
Why it matters: Resolving these issues is key to improving revenue in the Eye & Ear Care category.
Supportive ifManagement says supply and sales for Clear Eyes will improve in the next quarters.
Worry ifSupply issues will cause more revenue drops in the Eye & Ear Care category.
Why it matters: Lower organic sales growth may mean less demand. This could hurt future revenue.
Worry ifQ2 organic sales growth was below 1.0%.
Less concerning ifQ2 organic sales growth was above 3.0%.
Why it matters: Successful integration can boost revenue and profits. This helps long-term growth.
Supportive ifManagement says integration is going well. They see revenue from Breathe Right and LaCorium.
Worry ifManagement reports delays in integration. This affects revenue from the new products.
Why it matters: Lower free cash flow may show cash management issues. This can affect capital use.
Worry ifAdjusted free cash flow reported below $270 million.
Less concerning ifAdjusted free cash flow reported above $270 million.
Why it matters: Higher net debt can raise worries about financial health. It affects how debt is managed.
Worry ifNet debt is above $2 billion.
Less concerning ifNet debt is below $2 billion.